NL-OMON43272已完成不适用
A Phase 1/2 Multicenter Study of BMS-986012 in Subjects with Relapsed / Refractory Small Cell Lung Cancer (CA001-030) - CA001-030 BMS-986012 in Relapsed / Refractory Small Cell Lung Cancer
Bristol-Myers Squibb0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Signed Written Informed Consent
- •- Men and women at least 18 years of age with histological or cytological confirmed pulmonary SCLC
- •- Have relapsed after or are refractory to first line therapy and have not yet received two
- •or more lines of anticancer treatment
- •- Last exposure to anticancer therapy within 4 weeks or 5 half-lives (whichever is longer) prior to study drug administration
- •- At least one measurable lesion per RECIST v1.1
- •- Adequate organ function
- •- Comply with visit and treatment schedule, sample collection for laboratory tests, and treatment and follow-up
排除标准
- •- Known or suspected brain metastasis
- •- Non-pulmonary small cell cancer
- •- Acute or chronic medical illness
- •- Uncontrolled or significant cardiac disease
- •- Infection requiring systemic treatment
- •- Grade 2 or higher peripheral neuropathy
- •- Other concomitant malignancies (except unless complete remission was achieved 3 yrs prior to study entry)
- •- HIV-related disease, HIV+, HepB, HepC
- •- Allergies or adverse drug reaction
研究者
相似试验
进行中（未招募）
1 期
BMS-986012 in Relapsed/Refractory SCLCMedDRA version: 18.1Level: LLTClassification code 10041071Term: Small cell lung cancer stage unspecifiedSystem Organ Class: 100000004864Small Cell Lung CancerEUCTR2014-002372-89-NLBristol-Myers Squibb International Corporation170
进行中（未招募）
1 期
BMS-986012 in Relapsed/Refractory SCLCMedDRA version: 18.1Level: LLTClassification code 10041071Term: Small cell lung cancer stage unspecifiedSystem Organ Class: 100000004864Small Cell Lung CancerEUCTR2014-002372-89-BEBristol-Myers Squibb International Corporation170
进行中（未招募）
1 期
Study of BMS-986179 Administered in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid TumorsSolid tumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2016-000603-91-NLBristol-Myers Squibb International Corporation204
已完成
不适用
A Phase 1/2a Study of BMS-986179 Administered in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumorsall solid tumors in part 1 and only NSCLC, RCC, CRPC, SCCHN, melanoma and pancreatic cancer in part 2.advanced solid tumorscancerNL-OMON47607Bristol-Myers Squibb15
进行中（未招募）
1 期
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced CancersAdvanced Malignant TumorsMedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2015-004914-79-PLBristol-Myers Squibb International Corporation907